1 not yet recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Hydrocortisone (intrathecal): new trials by email Literature Review of Hydrocortisone (intrathecal) trials Research Report on Hydrocortisone (intrathecal)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML." Revumenib, Fludarabine, Cytarabine (Ara-C) - Leukemia, Myeloid, Acute | Phase 2 | Not yet recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 24 | 2026-08-31 | 2026-07-22 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-10-15 |
Leukemia, Myeloid, Acute (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Novartis Pharmaceuticals (1) · Therapeutic Advances in Childhood Leukemia Consortium (1)
Australia (1) · Israel (1) · South Korea (1) · Taiwan (1)
2025 (1)